Arrhythmias - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Arrhythmias - Pipeline Review, H1 2016', provides an overview of the Arrhythmias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arrhythmias and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Arrhythmias - The report reviews pipeline therapeutics for Arrhythmias by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Arrhythmias therapeutics and enlists all their major and minor projects - The report assesses Arrhythmias therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Arrhythmias Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Arrhythmias - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Arrhythmias pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Arrhythmias Overview 7 Therapeutics Development 8 Pipeline Products for Arrhythmias - Overview 8 Pipeline Products for Arrhythmias - Comparative Analysis 9 Arrhythmias - Therapeutics under Development by Companies 10 Arrhythmias - Therapeutics under Investigation by Universities/Institutes 11 Arrhythmias - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Arrhythmias - Products under Development by Companies 14 Arrhythmias - Products under Investigation by Universities/Institutes 15 Arrhythmias - Companies Involved in Therapeutics Development 16 Cynata Therapeutics Limited 16 Gilead Sciences, Inc. 17 Ono Pharmaceutical Co., Ltd. 18 Orion Oyj 19 SciFluor Life Sciences, LLC 20 SignPath Pharma Inc 21 Arrhythmias - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 aladorian sodium - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Antisense Oligonucleotides to Activate hERG1 for Long-QT Syndrome - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 efsevin - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 eleclazine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 EU-8120 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 GS-967 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 KN-93 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 landiolol - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 LH-021 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ORM-10103 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 PP-1 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecule for Arrhythmia - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 VKII-86 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Arrhythmias - Recent Pipeline Updates 49 Arrhythmias - Dormant Projects 50 Arrhythmias - Discontinued Products 52 Arrhythmias - Product Development Milestones 53 Featured News & Press Releases 53 May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development for Arrhythmias, H1 2016 8 Number of Products under Development for Arrhythmias - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Arrhythmias - Pipeline by Cynata Therapeutics Limited, H1 2016 16 Arrhythmias - Pipeline by Gilead Sciences, Inc., H1 2016 17 Arrhythmias - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 18 Arrhythmias - Pipeline by Orion Oyj, H1 2016 19 Arrhythmias - Pipeline by SciFluor Life Sciences, LLC, H1 2016 20 Arrhythmias - Pipeline by SignPath Pharma Inc, H1 2016 21 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Stage and Target, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 26 Number of Products by Stage and Route of Administration, H1 2016 28 Number of Products by Stage and Molecule Type, H1 2016 30 Arrhythmias Therapeutics - Recent Pipeline Updates, H1 2016 49 Arrhythmias - Dormant Projects, H1 2016 50 Arrhythmias - Dormant Projects (Contd..1), H1 2016 51 Arrhythmias - Discontinued Products, H1 2016 52
Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population iRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over tRead More...
U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposableRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.